alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 251–275 of 400 studies with an author at Brigham and Women's Hospital (US) (page 11 of 16) · 28,980 in the whole library · How the 0–100 score works

Download bibliography of these 400 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,457 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-12-05

ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The American journal of clinical nutrition 2009-05-27

Greater fish and omega-3 (n-3) polyunsaturated fatty acid (PUFA) intake may reduce dementia risk; however, previous studies have reported conflicting results, which were largely based on short-term follow-up. 4 key findings →

Participants: 5,395 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Nature reviews. Neurology 2019-12-11

The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement

✓ Peer-reviewed alzhub usefulness score 55 out of 100. European Heart Journal 2025-05-27

Vaccination is increasingly acknowledged as an effective preventive measure not only against specific infections, but also for the prevention of cardiovascular disease in high-risk patients. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Knowledge and practice of healthy behaviors for dementia and stroke prevention in a United States cohort

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Scientific Reports 2025-04-30

At least 45% of dementia and 60% of stroke cases are due to modifiable risk factors and could in part be prevented through healthy behavior. 3 key findings →

Design: cross-sectional Participants: 1,478 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia 2011-07-01

The Alzheimer's Association Research Roundtable convened a working group to review data on amyloid imaging related abnormalities (ARIA) in response to concerns raised by the Food and Drug Administration. 3 key findings →

Full summary, score breakdown and related studies → Original source Free full text

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 54 out of 100. JAMA neurology 2017-04-01

In all 6 patients (3 women and 3 men; mean age 61.8 years), the underlying clinical phenotype was associated with the regional distribution of the [18F]AV-1451 signal. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Immunity 2022-08-16

The apolipoprotein E4 (APOE4) allele is associated with an increased risk of Alzheimer disease and a decreased risk of glaucoma, but the underlying mechanisms remain poorly understood. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association Between Life's Simple 7 and Noncardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Journal of the American Heart Association 2016-10-20

The American Heart Association's LS7 score identified individuals who were vulnerable to multiple chronic nonvascular conditions. 4 key findings →

Participants: 6,506 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia (New York, N. Y.) 2017-08-05

Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Nature medicine 1996-10-01

Missense mutations in the presenilin 1 (PS1) gene cause the most common form of dominant early-onset familial Alzheimer's disease (FAD) and are associated with increased levels of amyloid beta-peptides (A beta) ending at residue 42 (A beta 42) in plasma and skin fibroblast media of gene carriers. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate

✓ Peer-reviewed alzhub usefulness score 54 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2017-01-01

Soluble oligomers of amyloid β-protein (oAβ) isolated from the brains of Alzheimer's disease (AD) patients have been shown experimentally (in the absence of amyloid plaques) to impair hippocampal synaptic plasticity, decrease synapses, induce tau hyperphosphorylation and neuritic dystrophy, activate microglial inflammation, and impair memory in normal adult rodents. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between anosognosia and neuropsychiatric symptoms in Alzheimer’s disease dementia patients

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Scientific Reports 2025-12-04

Anosognosia, the lack of awareness of memory decline, and Neuropsychiatric Symptoms (NPS) are prevalent and debilitating symptoms in Alzheimer's disease (AD) dementia. 4 key findings →

Design: longitudinal study Participants: 53 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Patients With Moderate to Severe Dementia Who Undergo Elective TKA Face Elevated Risks of Death, Delirium, and Intensive Interventions: A Large, Propensity-weighted Database Study

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Clinical Orthopaedics and Related Research 2025-05-13

After adjusting for potentially confounding variables such as age, gender, and comorbidities, we found that individuals with mild dementia (HR 1.74 [95% confidence interval (CI) 1.12 to 2.70]; p = 0.01) and moderate to severe dementia (HR 3.05 [95% CI 1.80 to 5.17]; p < 0.001) both demonstrated elevated hazards of death compared with patients without dementia. 5 key findings →

Participants: 156,596 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 2009-04-01

Discovery efforts for susceptibility loci for Alzheimer disease could benefit from the use of neuropathologic intermediate phenotypes as a complement to other approaches. 2 key findings →

Participants: 625 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends and Factors Associated with Place of Death for Individuals with Dementia in the United States

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of the American Geriatrics Society 2019-10-14

As ADRD deaths at home increase, the need for caregiver support and home-based palliative care may become more critical. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,036 records (3.6% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed